US2023241200A1PendingUtilityA1

Hiv pre-immunization and immunotherapy

84
Assignee: AMERICAN GENE TECH INT INCPriority: Jul 8, 2016Filed: Feb 10, 2023Published: Aug 3, 2023
Est. expiryJul 8, 2036(~10 yrs left)· nominal 20-yr term from priority
Inventors:Charles David PauzaHaishan LiTyler LahusenJeffrey A. Galvin
A61K 2239/38C12N 5/0636C12N 5/0634A61K 40/46A61K 40/11A61K 39/21A61P 31/18A61K 45/06A61K 39/12C07K 14/7158A61K 31/7105C12N 15/111A61K 35/14A61K 39/39C12N 7/00C12N 15/1132C12N 15/1138C12N 15/86C12N 2710/24143C12N 2740/16022C12N 2330/51C12N 2740/16034C12N 2740/16043A61K 35/17A61K 2039/545C12N 2310/14C12N 2310/141C12N 2320/32A61K 2035/124C12N 2510/00C12N 2740/15034C12N 2740/15043C12N 2740/15052C12N 2310/122C12N 2740/15021A61K 2039/55561
84
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates generally to immunization and immunotherapy for the treatment or prevention of HIV. In particular, the methods include in vivo and/or ex vivo enrichment of HIV-specific CD4+ T cells.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A lentiviral vector comprising at least one encoded genetic element, wherein the at least one encoded genetic element comprises
 at least two of: (i) a sequence comprising at least 80% sequence identity with SEQ ID NO: 1, (ii) a sequence comprising at least 80% sequence identity with SEQ ID NO: 2, and (iii) a sequence comprising at least 80% sequence identity with SEQ ID NO: 3; or   any two of: (iv) a sequence comprising at least 80% sequence identity with SEQ ID NO: 97, (v) a sequence comprising at least 80% sequence identity with SEQ ID NO: 6, and (vi) a sequence comprising at least 80% sequence identity with SEQ ID NO: 7.

Join the waitlist — get patent alerts

Track US2023241200A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.